Taltz® ▼ (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Taltz Summary of Product Characteristics (SmPC)

Taltz® ▼ (ixekizumab): How many patients developed uveitis with and without a prior history?

Treatment-emergent anterior uveitis has been reported in psoriasis, psoriatic arthritis and axial spondyloarthritis clinical trials. This response provides patient-reported history of uveitis where available.

Background Information

This response includes reports of anterior uveitis (MedDRA-preferred term "iridocyclitis") in psoriasis, psoriatic arthritis, and axSpA clinical trials. 

The most common extra-muscular-skeletal feature of spondyloarthritis is uveitis. Up to 50% of patients with AS/r-axSpA will experience uveitis, and the most common type is anterior uveitis. The occurrence of uveitis has been associated with HLA-B27 status and duration of the spondyloarthropathy.1

Uveitis as Adverse Drug Reaction

Uveitis is not listed as adverse drug reaction in the Taltz summary of product characteristics. 2

Exclusion Criteria in Ixekizumab Clinical Trials Related to Uveitis

Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis Trials

Patients were excluded from COAST-V and COAST-W if they had evidence of active anterior uveitis (an acute episode) within the last 4 weeks prior to baseline randomization. These patients were allowed to be rescreened only 1 time ≥4 weeks after resolution of acute symptoms. Other patients with a previous history of uveitis were allowed to be enrolled in the study.3,4

Non-radiographic Axial Spondyloarthritis

Patients were excluded from COAST-X if they had evidence of active anterior uveitis (an acute episode) within the last 42 days prior to baseline randomization. These patients were allowed to be rescreened only 1 time ≥4 weeks after resolution of acute symptoms. Other patients with a previous history of uveitis were allowed to be enrolled in the study.5

Psoriatic Arthritis Trials

Patients with active vasculitis or uveitis were excluded from participation in the phase 3 psoriatic arthritis clinical trials.6,7

Plaque Psoriasis Trials

No specific exclusion criteria for uveitis were included in the pivotal phase 3 plaque psoriasis clinical trials.8

History of Anterior Uveitis and Treatment-Emergent Adverse Events of Anterior Uveitis in Ixekizumab Clinical Trials

Note that multiple, different dosing regimens, including unapproved doses, are included in this response. Please refer to the Taltz Summary of Product Characteristics for approved dosing.2

New Onset and Flares of Anterior Uveitis in Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis Trials

See Table 1 for information on new onset and flares of anterior uveitis during the 16-week blinded dosing period of COAST-V and COAST-W. A brief description of clinical trials referenced in this response is available in Appendix: Brief Clinical Trial Descriptions.

Table 1. Treatment-Emergent Anterior Uveitisa in COAST-V and COAST-W 16-Week Double-Blind Treatment Period (Integrated) 9


PBO
N=190

IXE Q4W
N=195

IXE Q2W
N=181

Patients with history of anterior uveitis, n

41

38

47

Total patients with ≥1 TE-anterior uveitis, n

0

3

3

Patients with ≥1 TE-anterior uveitis and a history of anterior uveitis

0

2

2

Patients with ≥1 TE-anterior uveitis and no history of anterior uveitis

0

1

1

Abbreviations: IXE Q2W = ixekizumab 80 mg every 2 weeks; IXE Q4W = ixekizumab 80 mg every 4 weeks; MedDRA = Medical Dictionary for Regulatory Activities; PBO = placebo; TE = treatment-emergent.

a Acute anterior uveitis was identified using the preferred term “iridocyclitis” (MedDRA Version 21.0).

Of the 38 patients in the ixekizumab 80 mg Q4W treatment arm with a history of anterior uveitis, 2 patients experienced TE-anterior uveitis.7

Similarly, of the 47 patients in the ixekizumab 80 mg Q2W treatment arm with a history of anterior uveitis, 2 patients experienced TE-anterior uveitis.7

In each of the ixekizumab 80 mg treatment arms, there was 1 patient with no prior history of anterior uveitis that experienced TE-anterior uveitis.7

Reports of Anterior Uveitis Through 52 Weeks in Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis Trials

Across both studies, 20.1% of patients had a history of acute anterior uveitis, and 20 patients reported events of acute anterior uveitis. Of those patients who reported events of anterior uveitis during the trials, 15 had a prior history of the condition (see Table 2).10

One case resulted in ixekizumab treatment interruption, and 1 case resulted in permanent discontinuation of ixekizumab treatment. The EAIR for acute anterior uveitis though 52 weeks was 3.9 per 100 PY.10

Table 2. Treatment-Emergent Anterior Uveitisa Through 52 Weeks of COAST-V and COAST-W (Integrated)10

Patients with history of anterior uveitis, n (%)

145 (22.1)

Patients with ≥1 TE-anterior uveitis, n (%)

20 (3.1)

Patients with ≥1 TE-anterior uveitis and a history of anterior uveitis

15

Patients with ≥1 TE-anterior uveitis and no history of anterior uveitis

5

Acute anterior uveitis EAIR per 100 PYs

3.9

Abbreviations: EAIR = exposure-adjusted incidence rate; MedDRA = Medical Dictionary for Regulatory Activities; PY = patient-year; TE = treatment-emergent.

a Acute anterior uveitis was identified using the preferred term “iridocyclitis” (MedDRA Version 21.0). Active anterior uveitis cases were evaluated by ophthalmologists.

New Onset and Flares of Anterior Uveitis in Non-radiographic Axial Spondyloarthritis Trials

See Table 3 for information on new onset and flares of anterior uveitis during the double-blind treatment period of COAST-X. A brief description of the clinical trial referenced in this response is available in Appendix: Brief Clinical Trial Descriptions.

Table 3.  Treatment-Emergent Anterior Uveitisa in COAST-X 16-Week Double-Blind Treatment Periodb7

 

PBO
N=105

IXE Q4W
N=96

IXE Q2W
N=102

Patients with history of anterior uveitis, n

12

14

8

Total patients with ≥1 TE-uveitis, n

2

1

2

Patients with ≥1 TE-anterior uveitis and a history of anterior uveitis

2

1

2

Patients with ≥1 TE-anterior uveitis and no history of anterior uveitis

0

0

0

Abbreviations: IXE Q2W = ixekizumab 80 mg every 2 weeks; IXE Q4W = ixekizumab 80 mg every 4 weeks; PBO = placebo; TE = treatment-emergent.

a Acute anterior uveitis was identified using the preferred term “iridocyclitis” (MedDRA Version 21.0).

b Prior to biologic rescue with ixekizumab 80 mg Q2W.

Of the 14 patients in the ixekizumab 80 mg Q4W treatment arm with a history of anterior uveitis, 1 patient experienced TE-anterior uveitis.7

Of the 8 patients in the ixekizumab 80 mg Q2W treatment arm with a history of anterior uveitis, 2 patients experienced TE-anterior uveitis.7

In each of the ixekizumab 80 mg treatment arms, all patients with TE-anterior uveitis had a history of anterior uveitis.7

Incidence of Anterior Uveitis in All Axial Spondyloarthritis Trials

The incidence rate of anterior uveitis across all patients exposed to ixekuzmab in axSpA trials (N=929; 1336.2 PYs) as of April 2019 is 3.1 per 100 PYs.7

Preexisting and Treatment-Emergent Adverse Events of Anterior Uveitis in Psoriatic Arthritis Trials

Anterior uveitis (MedDRA-preferred term "iridocyclitis") was reported as a historical illness in 1 patient and as a preexisting condition in no patients randomized to ixekizumab 80 mg Q4W (N=454) in SPIRIT-P1 and SPIRIT-P2. Anterior uveitis was not reported as a preexisting condition and was reported as a historical illness in 1 patient in the phase 3 long-term efficacy trial SPIRIT-P3.7

No TEAEs of anterior uveitis were reported out of 1401 patients exposed to ixekizumab across psoriatic arthritis clinical trials as of March 21, 2019.7

Preexisting and Treatment-Emergent Adverse Events of Anterior Uveitis in Plaque Psoriasis Trials

Anterior uveitis was reported as a historical illness in 1 patient and as a preexisting condition in no patients randomized to ixekizumab through week 12 (N=2328) in UNCOVER -1, -2, and -3.7

Two (0.0%) TEAEs of uveitis were reported out of 6091 patients exposed to ixekizumab across plaque psoriasis clinical trials (including phase 1, phase 2, and phase 3) as of March 21, 2019.7

References

1. Khan MA, Haroon M, Rosenbaum JT. Acute anterior uveitis and spondyloarthritis: more than meets the eye. Curr Rheumatol Rep. 2015;17(9):59. https://dx.doi.org/10.1007/s11926-015-0536-x

2. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

3. Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599-611. http://dx.doi.org/10.1002/art.40753

4. van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441-2451. http://dx.doi.org/10.1016/s0140-6736(18)31946-9

5. Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53-64. http://dx.doi.org/10.1016/S0140-6736(19)32971-X

6. Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomized, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317-2327. http://dx.doi.org/10.1016/S0140-6736(17)31429-0

7. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

8. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711

9. Marzo-Ortega H, Mysler E, Tomita T, et al. Long-term safety of ixekizumab inpatients with radiographic axial spondyloarthritis/ankylosing spondylitis: An integrated analysis of COAST-V and COAST-W. Poster presented at: European League Against Rheumatism; June 12-15, 2019; Madrid, Spain.

10. Schwartzman S, Deodhar A, Kronbergs A, et al. Inflammatory bowel disease and anterior uveitis in patients treated with ixekizumab for radiographic axial spondyloarthritis: Results from two phase 3 studies through 52 weeks. Poster presented at: American College of Rheumatology/ARHP Annual Scientific Meeting; November 8-13, 2019; Atlanta, GA.

11. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87. http://dx.doi.org/10.1136/annrheumdis-2016-209709

12. A long-term efficacy and safety study of ixekizumab (LY2439821) in participants with active psoriatic arthritis (SPIRIT P3). ClinicalTrials.gov identifier: NCT02584855. Updated November 6, 2018. Accessed March 13, 2019. https://www.clinicaltrials.gov/ct2/show/NCT02584855?term=SPIRIT-P3&rank=1.

13. A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis. ClinicalTrials.gov identifier: NCT031129100. Updated May 3, 2019. Accessed June 24, 2019. https://www.clinicaltrials.gov/ct2/show/NCT03129100

Glossary

AS/r-axSpA = ankylosing spondylitis/radiographic axial spondyloarthritis

bDMARD = biologic disease-modifying antirheumatic drug

EAIR = exposure adjusted incidence rate

MedDRA = Medical Dictionary for Regulatory Activities

nr-axSpA = nonradiographic axial spondyloarthritis

PsA = psoriatic arthritis

PY = patient-years

Q2W = every 2 weeks

Q4W = every 4 weeks

TEAE = treatment-emergent adverse event

TE = treatment-emergent

TNF = tumor necrosis factor

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Appendix: Brief Clinical Trial Descriptions

Plaque Psoriasis Trials

  • UNCOVER-1, -2, and -3 (N=3866) phase 3 trials in moderate-to-severe plaque psoriasis were integrated to evaluate the safety of ixekizumab in comparison to placebo up to 12 weeks after treatment initiation.

  • The phase 3 trials examined the efficacy and safety of ixekizumab compared with placebo and etanercept (UNCOVER-2 and -3) during induction treatment and vs placebo in maintenance (UNCOVER-1 and -2).8

Figure 1. Induction (UNCOVER-1, -2, -3) and Maintenance (UNCOVER-1, -2) Dosing Period Study Designs8

Abbreviations: ETN = etanercept; IXE Q2W = ixekizumab 80 mg every 2 weeks; IXE Q4W = ixekizumab 80 mg every 4 weeks; IXE Q12W = ixekizumab 80 mg every 12 weeks; PBO = placebo; R = randomization; sPGA = static Physician Global Assessment.

Notes:
ETN arm was not included in UNCOVER-1.

Responders (sPGA 0 or 1) to ixekizumab at week 12 were re-randomized to receive IXE Q4W, IXE Q12W, or PBO.

Nonresponders to ETN at week 12 in UNCOVER-2 were switched to IXE Q4W (without a 160 mg starting dose) after a 4-week washout period.

Nonresponders to PBO at week 12 received a 160 mg starting dose of ixekizumab followed by IXE Q4W.

(dotted line) = relapse (sPGA≥3).

UNCOVER-3 is not represented in maintenance period design as the extension period consisted of open-label treatment with IXE Q4W.

 Some dosing schedules shown in Figure 1 are not consistent with the approved dosing schedule for plaque psoriasis in the Taltz summary of product characteristics. Please refer to the Taltz summary of product characteristics for approved dosing.2

Psoriatic Arthritis Trials

  • SPIRIT-P1 (N=417) is a phase 3, 24-week double-blind, placebo-controlled trial with an active reference arm in patients with active PsA who are naïve to bDMARDs with an extension period of up to 3 years.11

  • SPIRIT-P2 (N=363) is a phase 3, 24-week double-blind, placebo-controlled trial in patients with active PsA and an inadequate response or intolerance to TNF inhibitor, with an extension period of up to 3 years.6

  • SPIRIT-P3 (N=570) consists of a 36-week open-label period followed by a randomized double-blind withdrawal period from week 36 to week 104. This trial is being conducted in patients naïve to bDMARDs.12

Axial Spondyloarthritis Trials

  • COAST-V (N=341) is a phase 3, 16-week double-blind, placebo-controlled trial with an active reference arm and a dose double-blind extension period to 52 weeks in patients with active AS/r-axSpA who are naive to bDMARDs.4

  • COAST-W (N=316) is a phase 3, 16-week double-blind, placebo-controlled trial with a dose double-blind extension period to 52 weeks in patients with active AS/r-axSpA and an inadequate response or intolerance to 1 or 2 TNF inhibitors.3

  • COAST-X (N=303) is a phase 3, 52-week double-blind, placebo-controlled trial in patients with nr-axSpA who are naive to bDMARDs.5

  • COAST-Y (N=750) is a phase 3, 104-week, long-term extension trial including a double-blind, placebo-controlled 40-week randomized withdrawal-retreatment period in patients with axial spondyloarthritis who have completed the final study visit in COAST-V, COAST-W, or COAST-X.13

Date of Last Review: October 04, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question